Venus Remedies Limited has issued a regulatory update regarding the correction of UDIN (Unique Document Identification Number) for its financial results for the quarter ended September 30, 2025. The pharmaceutical company identified and rectified a clerical error in the auditor identification numbers used in its quarterly financial reporting.

UDIN Correction Details

The company's statutory auditors inadvertently used the same UDIN in both standalone and consolidated limited review reports, when separate identification numbers should have been generated for each report type. The correction addresses this administrative oversight to ensure proper regulatory compliance.

The company clarified that two separate UDINs were duly generated for the standalone and consolidated limited review reports, and the duplication was purely clerical in nature. This administrative correction does not impact the financial data or results previously reported.

Regulatory Compliance

Venus Remedies has resubmitted the complete set of financial results with the correct UDIN to both BSE Limited and National Stock Exchange of India Limited. The correction ensures compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company's communication was signed by Neha, Company Secretary (M. No. F8374), and digitally authenticated on January 13, 2026. This correction demonstrates the company's commitment to maintaining accurate regulatory documentation and transparency in its financial reporting processes.

Company Operations

Venus Remedies Limited operates multiple manufacturing units across India and Germany, with its registered office in Chandigarh and corporate office in Panchkula, Haryana. The company maintains certifications including AEO (Authorized Economic Operator) status with Indian Customs and operates as a Responsible Export Organization.

Venus Remedies Limited has received marketing authorisation from Indonesian regulatory authorities for its antibiotic combination drug Ceftazidime + Avibactam. This regulatory approval marks an important development in the company's international market expansion efforts.

Regulatory Approval Details

The marketing authorisation granted by Indonesian authorities allows Venus Remedies to commercialise its antibiotic combination in the Indonesian pharmaceutical market. The approved product combines Ceftazidime with Avibactam, representing the company's advanced antibiotic formulation capabilities.

Market Expansion Significance

This Indonesian marketing authorisation represents a strategic milestone for Venus Remedies' international operations. The approval enables the company to enter the Indonesian healthcare market with its specialised antibiotic combination, potentially contributing to the company's revenue diversification across international markets.

Product Portfolio Enhancement

The Ceftazidime + Avibactam combination adds to Venus Remedies' portfolio of approved pharmaceutical products in international markets. This regulatory success demonstrates the company's ability to meet international quality standards and regulatory requirements for complex antibiotic formulations.